Low Vitamin D and TSH Emerge as Striking Biochemical Signatures of Ovarian Syndrome

Polycystic ovary syndrome, recently reframed in parts of the endocrine literature as polyendocrine metabolic ovarian syndrome, has long been treated as a disorder defined by its reproductive hormones: elevated luteinizing hormone, a skewed LH-to-FSH ratio, and the ovarian and metabolic consequences that follow. A new case-control study from Peshawar, Pakistan, adds two quieter players to that biochemical picture. Researchers report that women with the syndrome carried dramatically lower concentrations of vitamin D and measurably lower thyroid-stimulating hormone than age-matched controls, and that both markers remained independently associated with case status even after accounting for the classical gonadotropin profile. The work, published in BMC Endocrine Disorders, offers one of the more detailed biochemical portraits of the condition in a South Asian cohort to date.

The study enrolled 160 women of reproductive age at Lady Reading Hospital, dividing them evenly into 80 cases and 80 controls. Cases were diagnosed using the Rotterdam criteria, the internationally accepted framework that requires two of three features: irregular or absent ovulation, clinical or biochemical signs of elevated androgens, and the characteristic polycystic ovarian morphology on ultrasound. Controls were matched by age, a design choice intended to strip away the confounding influence of life stage on both reproductive hormones and vitamin D metabolism. Each participant provided serum for measurement of luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, and 25-hydroxyvitamin D, the circulating form of the vitamin that serves as the standard benchmark of nutritional vitamin D status.

The headline numbers are striking. Women with the syndrome had a median 25-hydroxyvitamin D concentration of 12.88 nanograms per milliliter, compared with 30.06 nanograms per milliliter in controls, a difference so large that the associated effect size reached a Spearman correlation coefficient of 0.77, a value rarely seen in human endocrine studies. To put those figures in clinical context, a value below 20 nanograms per milliliter is conventionally labeled deficiency, and below 10 is often considered severe deficiency. The case group’s median therefore sits deep within deficient territory, while the control median falls comfortably in the sufficient range. Thyroid-stimulating hormone told a subtler story: cases averaged 1.67 micro-international units per milliliter against 2.49 in controls, a statistically robust difference with a moderate effect size, yet both medians remained inside the standard laboratory reference interval.

That last point matters, and the authors are careful to underline it. A lower TSH value within the normal range is not the same as thyroid disease, and the study explicitly cautions that the group difference should not be read as evidence of abnormal thyroid function in either direction. What the finding suggests instead is that the hypothalamic-pituitary-thyroid axis may sit at a different set point in women with the syndrome, or that the syndrome and TSH variation share an upstream driver. Speculation about mechanism must remain restrained here, because the design is cross-sectional and associative. The researchers measured hormones at a single time point and cannot say whether low vitamin D and low TSH precede the syndrome, follow from it, or co-occur as parallel consequences of a shared metabolic or inflammatory state.

To move beyond simple group comparisons, the team turned to Firth-penalized binary logistic regression, a statistical technique chosen for a specific technical reason. In datasets where a predictor or combination of predictors nearly perfectly separates cases from controls, a problem statisticians call quasi-complete separation, standard maximum-likelihood logistic regression produces unstable, inflated coefficient estimates that can diverge toward infinity. Firth’s penalization adds a corrective term to the likelihood function, shrinking estimates toward plausible values and yielding finite, interpretable odds ratios even in small or sharply separated samples. This methodological choice lends credibility to the adjusted estimates, which might otherwise have been dismissed as artifacts of overfitting.

The penalized models delivered three independent correlates. Each additional nanogram per milliliter of vitamin D was associated with a 65 percent reduction in the odds of case status, with an adjusted odds ratio of 0.35 and a 95 percent confidence interval of 0.19 to 0.65. Each additional micro-international unit per milliliter of TSH was associated with dramatically lower odds, an adjusted odds ratio of 0.018, though the very wide confidence interval of 0.001 to 0.251 reflects the steepness of the relationship and the penalization required to estimate it. Higher luteinizing hormone, by contrast, pushed odds upward, with an adjusted odds ratio of 1.49 per unit increase. In plain terms, the vitamin D signal and the TSH signal each carried information about case status that the reproductive hormones alone did not capture.

Discrimination analysis sharpened the picture further. When the researchers plotted receiver-operating-characteristic curves, vitamin D alone achieved an area under the curve of 0.945 in this sample, a figure conventionally described as excellent and approaching the separation one would expect from a diagnostic rather than a merely associative marker. TSH managed 0.788 and luteinizing hormone 0.779, both respectable but clearly weaker. The authors resist the tempting leap from discrimination to screening, and rightly so. An in-sample AUC from a case-control design overstates real-world performance, because cases and controls were deliberately balanced and enriched. In the general population, where the syndrome’s prevalence is far lower and the spectrum of vitamin D status is broader, a single blood test would almost certainly perform less impressively.

The vitamin D connection itself is not entirely new to the literature. Previous studies across multiple populations have reported lower 25-hydroxyvitamin D concentrations in women with the syndrome, and proposed mechanisms range from the vitamin’s role in insulin signaling and ovarian steroidogenesis to its influence on anti-Müllerian hormone production and chronic low-grade inflammation. Vitamin D receptors are expressed in ovarian tissue, and the vitamin’s hydroxylase enzymes participate in local steroid hormone synthesis, giving plausible biological routes by which deficiency could interact with the disorder’s core endocrine disturbances. What this study adds is the demonstration that, in a South Asian cohort where deficiency is widespread for reasons of diet, clothing practices, and limited sun exposure, the deficiency signal is nonetheless sharply differentiated between women with and without the syndrome, and that it survives adjustment alongside gonadotropins.

The TSH finding is more novel and more puzzling. Some prior work has suggested a higher prevalence of thyroid autoimmunity and subclinical hypothyroidism among women with the syndrome, which would predict higher rather than lower TSH. The Peshawar cohort shows the opposite direction of shift, albeit within normal limits. One possibility is population-specific variation in iodine status, thyroid antibody prevalence, or body composition, all of which influence TSH. Another is that the association reflects shared regulation, since both TSH secretion and ovarian function are modulated by metabolic signals such as leptin and insulin. Without longitudinal follow-up or mechanistic sampling, these hypotheses remain open. The authors are appropriately explicit that their findings are associative and do not establish causality or screening utility, a restraint that distinguishes the paper from much of the vitamin D literature.

For clinicians and researchers, the study’s practical significance lies in its characterization of a population where the syndrome’s biochemical profile may differ from the Western templates that dominate textbooks. South Asian women face high rates of vitamin D deficiency and distinct metabolic risk patterns, and endocrine reference behavior can vary accordingly. The results argue for measuring 25-hydroxyvitamin D in women evaluated for the syndrome in this region, not as a diagnostic test but as part of a fuller metabolic assessment, and they flag TSH variation within the normal range as a variable worth tracking in future cohorts. Larger prospective studies, ideally with repeated sampling and intervention trials of vitamin D repletion, will be needed to determine whether correcting deficiency alters the syndrome’s trajectory. Until then, this study stands as a carefully executed, statistically disciplined snapshot linking two understudied biochemical markers to one of the most common endocrine disorders of reproductive-age women.

Subject of Research: Associations of vitamin D status and thyroid-stimulating hormone variation with polyendocrine metabolic ovarian syndrome in South Asian women

Article Title: Vitamin D status and TSH variation as independent biochemical correlates of polyendocrine metabolic ovarian syndrome: a case–control study

Article References: Ullah, M. A., Tariq, A., Parvez, K. F., Ashraf, M., Inayat, F., & Zeb, M. A. (2026). Vitamin D status and TSH variation as independent biochemical correlates of polyendocrine metabolic ovarian syndrome: a case–control study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02482-w

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02482-w

Keywords: polyendocrine metabolic ovarian syndrome, PCOS, vitamin D, TSH, luteinizing hormone, case-control study, penalized regression, endocrine disorders, South Asian women, Rotterdam criteria, 25-hydroxyvitamin D, reproductive endocrinology